Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl-hydantoins

Archiv der Pharmazie

Volumn 344, Issue 4, 2011, Pages 231-241

  Byrtus, Hanna ^a   Obniska, Jolanta ^a   Czopek, Anna ^a   Kaminski K ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

5 cyclopropyl 5 phenyl hydantoins; Anticonvulsant activity; Imidazolidine 2,4 diones; N Mannich bases

Indexed keywords

3 [(4 BENZYLPIPERAZIN 1 YL) METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [(4 BENZYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3 [(4 ETHYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [(4 HYDROXYETHYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [(4 METHYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3 [(4 METHYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [(4 PHENYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 PHENYL IMIDAZOLIDINE 2,4 DIONE; 3 [(4 PHENYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [[4 (2 FLUOROPHENYL)PIPERAZIN 1 YL] METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [[4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3 [[4 (2,6 DICHLOROBENZYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3 [[4 (2,6 DICHLOROBENZYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [[4 (3 METHYLBENZYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3 [[4 (3 METHYLBENZYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [[4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3 [[4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [[4 (4 CHLOROBENZYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3 [[4 (4 CHLOROBENZYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [[4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] METHYL] 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; 3 [[4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 3[(4 PHENYLPIPERAZIN 1 YL)METHYL] 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)HYDANTOIN; 5 CYCLOPROPYL 5 (4 CHLOROPHENYL)IMIDAZOLIDINE 2,4 DIONE; 5 CYCLOPROPYL 5 PHENYLHYDANTOIN; 5 CYCLOPROPYL 5 PHENYLIMIDAZOLIDINE 2,4 DIONE; ETHOSUXIMIDE; HYDANTOIN DERIVATIVE; MANNICH BASE; PENTETRAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE; ANTICONVULSANT ACTIVITY; ARTICLE; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; EPILEPSY; GRAND MAL EPILEPSY; HUMAN; NEUROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STUDY; ROTAROD TEST; SEIZURE; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; HYDANTOINS; MALE; MANNICH BASES; MICE; MOLECULAR STRUCTURE; NEUROTOXICITY SYNDROMES; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953774093     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201000241     Document Type: Article

References (24)

1. O. J. McNamara, Drugs effective in the therapy of the epilepsies, in The Pharmacological Basis of Therapeutics (Eds.: J. G. Hardman, L. E. Limbird, A. G. Gilman), McGraw-Hill, New York 2001, pp. 521-548.
2. W. Löscher, D. Schmidt, Epilepsy Res. 2006, 69, 183-272.
3. J. A. Cramer, S. Mintzer, J. Wheless, R. H. Mattson, Expert. Rev. Neurother. 2010, 10 (6), 885-891.
4. M. G. Wong, J. A. Defina, P. R. Andrews, J. Med. Chem. 1986, 29, 562-572.
5. E. Estrada, A. Pena, Bioorg, Med. Chem. 2000, 8, 2755-2770.
6. L. Bruno-Blanch, J. Gálvez, R. Garcia-Domenach, Bioorg. Med. Chem. Lett. 2003, 13, 2749-2754.
7. J. R. Pollard, J. French, Lancet Neurol. 2006, 5, 1064-1067.
8. M. Bialer, S. I. Johannessen, H. J. Kupferberg, R. H. Levy, E. Perucca, T. Tomson, Epilepsy Res. 2007, 73, 1-52.
9. B. Bennett, A. Matagne, P. Michel, M. Leonard, M. Cornet, M. A. Meeus, N. Toublanc, Neurotherapeutics 2007, 4, 117-122.
10. J. Obniska, A. Zagórska, Il Farmaco 2003, 58, 1227-1234.
11. J. Obniska, K. Kamiński, D. Skrzyńska, J. Pichór, Eur. J. Med. Chem. 2009, 44, 2224-2233.
12. J. Obniska, M. Kopytko, A. Zagórska, I. Chlebek, K. Kamiński, Arch. Pharm. Chem. Life Sci. 2010, 343, 333-341.
13. J. Obniska, H. Byrtus, K. Kamiński, M. Pawłowski, M. Szczesio, J. Karolak-Wojciechowska, Bioorg. Med. Chem. 2010, 18, 6134-6142.
14. H. Marona, A. Gunia, K. Słoczyńska, Anna Rapacz, Barbara Filipek, Marek Cegła, W. Opoka, Acta Pol. Pharm. Drug Res. 2009, 66, 571-578.
15. T. Dylag, M. Zygmund, D. Macia̧g, J. Handzlik, M. Bendrski, B. Filipek, K. Kieć-Kononowicz, Eur. J. Med. Chem. 2004, 39 (12), 1013-1027.
16. L. H. Goodson, J. L. Honigberg, J. L. Lehman, W. H. Burton, J. Org. Chem. 1960, 25, 1920-1924.
17. H. S. White, Epilepsia 2003, 44, 2-8.
18. M. A. Rogawski, Epilepsy Res. 2006, 68, 23-26.
19. R. L. Krall, J. K. Penry, B. G. White, H. J. Kupferberg, E. A. Swinyard, Epilepsia 1978, 19, 409-428.
20. H. J. Kupferberg, Epilepsia 1989, 30 (Suppl.), 51-56.
21. N. W. Dunham, T. A. Miya, J. Am. Pharm. Assoc. Sci. 1957, 46, 208-209.
22. R. F. Kaminski, M. R. Livingood, M. A. Rogawski, Epilepsia 2004, 45, 864-867.
23. R. Thirumurugan, D. Sriram, A. Saxena, J. P. Stables, P. Yogeeswari, Bioorg. Med. Chem. 2006, 14, 3106-3112.
24. H. S. White, J. H. Woodhead, K. S. Wilcox, J. P. Stables, H. J. Kupferberg, H. H. Wolf, Discovery and preclinical development of antiepileptic drugs, in Antiepileptic Drugs (Eds.: R. H. Levy, R. H. Mattson, B. S. Meldrum, E. Perucca), Lippincott, Philadelphia 2002, pp. 36-48.